A TFEB and V-ATPase-mediated lysosomal stress sensing pathway in tauopathy
tau 蛋白病中 TFEB 和 V-ATPase 介导的溶酶体应激传感途径
基本信息
- 批准号:10172236
- 负责人:
- 金额:$ 52.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse effectsAffectAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAstrocytesAtlasesAutophagocytosisBehavioralBindingBrainCell NucleusCommunitiesCytoplasmDataDependenceDiseaseExhibitsFrontotemporal DementiaGene ExpressionGenesGenetic TranscriptionGoalsHippocampus (Brain)HomeostasisHumanImmuneImmune responseImpairmentIn VitroKnock-in MouseKnockout MiceLinkLysosomesMediatingMicrogliaMusMutateNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesNeurogliaNeuronsNuclearNuclear TranslocationPathogenesisPathologyPathway interactionsPhenotypePhysiologicalPost-Translational Protein ProcessingProgram Research Project GrantsPropertyProteomeProteomicsProxyRegulationRegulatory PathwayResearchResearch PersonnelRoleSignal PathwaySignal TransductionStressSystemTauopathiesTechnologyTestingTransgenic MiceUp-RegulationWild Type Mouseactivating transcription factorbasebrain healthcombatcomparativedata integrationfunctional declinehyperphosphorylated tauimmunoregulationin vivoinsightlysosomal proteinsmetabolomemetabolomicsmouse modelmutantnovelprogramspromoterprotein metaboliteresponsesynergismtau Proteinstau aggregationtherapeutic targettranscription factortranscriptome sequencingtranscriptomicsvacuolar H+-ATPase
项目摘要
Abstract
Tauopathies consist of a group of diseases, including frontotemporal dementias and the most common form
Alzheimer’s disease, and are characterized by the accumulation of intracellular neurofibrillary tangles (NFTs)
composed of aggregates of hyperphosphorylated Tau protein and extensive neurodegeneration. Accumulating
evidence has implicated impaired autophagy-lysosome pathway in neurodegenerative diseases including
Alzheimer’s disease. The Transcription Factor EB (TFEB) was discovered as a master regulator of cellular
clearance through coordinated expression of autophagy and lysosomal target genes. We have found that
TFEB is highly efficacious in ameliorating Tau/NFT pathology and behavioral deficits in Tau transgenic mice
while exhibiting no adverse effect on wild-type mice, supporting the premise that TFEB may serve as potential
therapeutic target. The overarching goal of this project is to investigate a Tau-induced TFEB lysosome-to-
nucleus signaling pathway regulating lysosomal homeostasis and cellular clearance in physiological and
tauopathy conditions and to identify strategies to augment this pathway for enhanced cellular clearance.
Specifically, through proteomics analysis of tauopathy mouse models, we will identify how Tau pathology
induces unique TFEB post-translational modifications and nuclear signaling. By leveraging the powerful
lysosomal purification and profiling system made available by the Program Project Grant investigators, we will
test how Tau pathology alters the lysosomal proteome, metabolome, and pH, the latter is essential for
lysosomal function and critically controlled by the vacuolar ATPase (V-ATPase). Accordingly, we will test the
specific TFEB/V-ATPase signaling in Tau pathogenesis and downstream glia and immune response. This
project is an integral component of the Program Project Grant aimed at understanding how lysosomal function
is regulated through lysosome-to-nucleus signaling pathways, how these pathways are changed in aging and
Alzheimer’s disease, and how to harness these regulatory pathways to promote brain health, combat age-
associated functional decline, and delay neurodegenerative diseases. This project, together with the
collaborative efforts of the Program Project Grant, will create a first-in-class Aging- and Tauopathy-associated
Lysosomal atlas (ATLas) of the lysosomal proteome and metabolome for mouse cortex and hippocampus
which will be made broadly available to the research community.
摘要
Tauopathies由一组疾病组成,包括额颞叶痴呆和最常见的形式
阿尔茨海默病,其特征在于细胞内神经元缠结(NFT)的积累
由过度磷酸化的Tau蛋白聚集体和广泛的神经变性组成。积累
有证据表明,神经退行性疾病中的自噬-溶酶体途径受损,
老年痴呆症转录因子EB(TFEB)被发现是细胞凋亡的主要调节因子。
通过自噬和溶酶体靶基因的协调表达清除。我们发现
TFEB在改善Tau转基因小鼠中的Tau/NFT病理和行为缺陷方面是高度有效的
同时对野生型小鼠没有表现出不利影响,支持TFEB可能作为潜在的
治疗靶点该项目的总体目标是研究Tau诱导的TFEB溶酶体-
核信号通路调节溶酶体稳态和细胞清除在生理和
本发明的目的是提供一种用于治疗tau蛋白病病症的方法,并鉴定增强该途径以增强细胞清除的策略。
具体来说,通过蛋白质组学分析tau蛋白病小鼠模型,我们将确定如何Tau病理
诱导独特的TFEB翻译后修饰和核信号传导。通过利用强大的
溶酶体纯化和分析系统由计划项目赠款研究人员提供,我们将
测试Tau病理学如何改变溶酶体蛋白质组,代谢组和pH值,后者对于
溶酶体的功能和关键控制的液泡ATP酶(V-ATP酶)。因此,我们将测试
特异性TFEB/V-ATP酶信号转导在Tau发病机制和下游神经胶质细胞和免疫应答中的作用。这
该项目是该计划项目赠款的一个组成部分,旨在了解溶酶体的功能
是通过溶酶体到细胞核的信号通路调节的,这些通路在衰老过程中是如何变化的,
阿尔茨海默病,以及如何利用这些调节途径来促进大脑健康,对抗年龄-
相关的功能下降,并延缓神经退行性疾病。该项目与
计划项目赠款的合作努力,将创造一流的老化和Tauopathy相关
小鼠皮层和海马的溶酶体蛋白质组和代谢组的溶酶体图谱(ATLas)
这将广泛提供给研究界。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hui Zheng其他文献
Hui Zheng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hui Zheng', 18)}}的其他基金
A TFEB and V-ATPase-mediated lysosomal stress sensing pathway in tauopathy
tau 蛋白病中 TFEB 和 V-ATPase 介导的溶酶体应激传感途径
- 批准号:
10413975 - 财政年份:2021
- 资助金额:
$ 52.19万 - 项目类别:
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease
衰老和阿尔茨海默病中的溶酶体调节和信号传导
- 批准号:
10172231 - 财政年份:2021
- 资助金额:
$ 52.19万 - 项目类别:
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease
衰老和阿尔茨海默病中的溶酶体调节和信号传导
- 批准号:
10413970 - 财政年份:2021
- 资助金额:
$ 52.19万 - 项目类别:
A TFEB and V-ATPase-mediated lysosomal stress sensing pathway in tauopathy
tau 蛋白病中 TFEB 和 V-ATPase 介导的溶酶体应激传感途径
- 批准号:
10583544 - 财政年份:2021
- 资助金额:
$ 52.19万 - 项目类别:
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease
衰老和阿尔茨海默病中的溶酶体调节和信号传导
- 批准号:
10655043 - 财政年份:2021
- 资助金额:
$ 52.19万 - 项目类别:
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease
衰老和阿尔茨海默病中的溶酶体调节和信号传导
- 批准号:
10765848 - 财政年份:2021
- 资助金额:
$ 52.19万 - 项目类别:
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease
衰老和阿尔茨海默病中的溶酶体调节和信号传导
- 批准号:
10614231 - 财政年份:2021
- 资助金额:
$ 52.19万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 52.19万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 52.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 52.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 52.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 52.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 52.19万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 52.19万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 52.19万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 52.19万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 52.19万 - 项目类别:
Discovery Grants Program - Individual